The Journal of Experimental Medicine
VeriKine-HS Human IFN-Beta
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published 6 December 2004. doi:10.1084/jem.20040795
Rockefeller University Press, 0022-1007 $8.00
JEM, Volume 200, Number 11, 1383-1393
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 4392K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lanoue, A.
Right arrow Articles by McKenzie, A. N.J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lanoue, A.
Right arrow Articles by McKenzie, A. N.J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
SIGN-R1 Contributes to Protection against Lethal Pneumococcal Infection in Mice

Astrid Lanoue1, Menna R. Clatworthy2, Philippa Smith1, Sheila Green1, Michael J. Townsend1, Helen E. Jolin1, Kenneth G.C. Smith2, Padraic G. Fallon3, and Andrew N.J. McKenzie1

1 Laboratory of Molecular Biology, Medical Research Council, Cambridge CB2 2QH, England, UK
2 Cambridge Institute for Medical Research and Department of Medicine, University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, Cambridge CB2 2XY, England, UK
3 Department of Biochemistry, Trinity College, Dublin 2, Ireland

Address correspondence to Andrew N.J. McKenzie, Laboratory of Molecular Biology, Medical Research Council, Hills Rd., Cambridge CB2 2QH, England, UK. Phone: 44-1223-402350; Fax: 44-1223-412178; email: anm{at}mrc-lmb.cam.ac.uk

Rapid clearance of pathogens is essential for successful control of pyogenic bacterial infection. Previous experiments have shown that antibody to specific intracellular adhesion molecule-grabbing nonintegrin (SIGN)-R1 inhibits uptake of capsular polysaccharide by marginal zone macrophages, suggesting a role for SIGN-R1 in this process. We now demonstrate that mice lacking SIGN-R1 (a mouse homologue of human dendritic cell–SIGN receptor) are significantly more susceptible to Streptococcus pneumoniae infection and fail to clear S. pneumoniae from the circulation. Marginal zone and peritoneal macrophages show impaired bacterial recognition associated with an inability to bind T-independent type 2 antigens such as dextran. Our work represents the first evidence for a protective in vivo role for a SIGN family molecule.

Key Words: DC-SIGN • marginal zone macrophages • microbial infection • innate immunity • lectin

A. Lanoue and M.R. Clatworthy contributed equally to this work.

M.J. Townsend's present address is Dept. of Immunology and Infectious Diseases, Harvard School of Public Health, Rm. 205, 651 Huntingdon Ave., Boston, MA 02115.

Abbreviations used in this paper: aa, amino acids; CRD, carbohydrate recognition domain; MZ, marginal zone; MZM, MZ macrophage; PC, phosphorylcholine; PRR, pattern recognition receptor; SIGN, specific intracellular adhesion molecule-grabbing nonintegrin; TI-2, thymus independent type 2.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS